Topic:

April 2024

AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis

https://www.lupuscanada.org/wp-content/uploads/AZD1222_PhIII-US-HLR_RNS.pdf

Lupus Blog Articles: Lupus lorem ipsum dolor sit amet est requiem deste natur.

Supporting Lupus Canada During Canada Post Strike

Awareness & CommunityCommunity & Awareness
Article
Read

New Resource: CANVAS Network for Vaccine Safety

Awareness & CommunityCommunity & Awareness
Article
Read

Exploring Cognitive Fatigue and Brain Function in Lupus: New MRI Study Reveals Insights into Cognitive Impairment Mechanisms

Catalyst GrantNews & Events
Article
Read